看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。8 o. j! v `2 b _
. l+ e: q R$ |9 w% p. l+ R5 s
$ ]4 }, j; T8 n) a
Currently available feasibility data for possible combination strategies.
9 i1 e+ _9 Z. p7 O. b3 U0 B- v————————————————————————————————
6 {* }/ z; X! X2 HCombination Feasibility according to preliminary data
9 s: c% M7 Q0 `! M+ ?——————————————————————————————————' }' l# ^" W- Z% P: B! w$ x
Bevacizumab + sorafenib Yes, reduced dose
+ M5 O$ g) |3 ^9 ^* [Bevacizumab + sunitinib† No
; H, N* M, h, IBevacizumab + temsirolimus Yes 6 b1 x$ \$ l p# H+ c
Bevacizumab + everolimus Yes " X5 X+ ^0 f2 J- Q# w
Sorafenib + sunitinib ?
; U4 E! d2 h9 TSorafenib + temsirolimus Yes, reduced dose ' T" I+ k* F+ h
Sorafenib + everolimus Yes, reduced dose 8 P O3 L8 d' f: b0 v' M8 i- n
Sunitinib + temsirolimus† No
4 i/ g" |8 f/ BSunitinib + everolimus ? 9 p. i# H q/ V2 G( ?
Temsirolimus + everolimus ?
, L; G, I* e, n————————————————————0 e8 ^4 B$ v+ T$ |) A3 U) B, b M1 [
†Led to US FDA warning.+ c+ F! m9 F$ B' k$ d
?: As yet unattempted combination.
$ V2 T z* S( E/ I$ f" q- c |